Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04058145
Title AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

oropharynx cancer

head and neck squamous cell carcinoma

Therapies

Pembrolizumab + Plerixafor

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.